Quince TherapeuticsQNCX
Market Cap: $32.3M
About: Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.
Employees: 32
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
2.5% less ownership
Funds ownership: 16.94% [Q1] → 14.43% (-2.5%) [Q2]
5% less funds holding
Funds holding: 44 [Q1] → 42 (-2) [Q2]
17% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 12
39% less capital invested
Capital invested by funds: $7.69M [Q1] → $4.67M (-$3.02M) [Q2]
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Research analyst outlook
We haven’t received any recent analyst ratings for QNCX.